Sander Bins

1.8k citations

59 papers · 1.2k indexed · h-index 17

Oncology top 5%
- Cancer Immunotherapy and Biomarkers 20
- Pancreatic and Hepatic Oncology Research 12
- Colorectal Cancer Treatments and Studies 10
- Drug Transport and Resistance Mechanisms 8
- CAR-T cell therapy research 5
Pharmacology top 5%
Pulmonary and Respiratory Medicine top 10%
- Lung Cancer Treatments and Mutations 9
- Prostate Cancer Treatment and Research 5
Cancer Research
Hematology top 10%
Molecular Biology
- Cancer therapeutics and mechanisms 4

Co-authors: Ron H.J. Mathijssen Ron H. N. van Schaik Femke M. de Man Andrew K.L. Goey Esther Oomen‐de Hoop Stijn L.W. Koolen Joachim G.J.V. Aerts Reno Debets
Cited by: Oncology Pharmacology Pulmonary and Respiratory Medicine
Journals: Annals of Oncology (9 papers)Clinical Pharmacokinetics (5 papers)Clinical Cancer Research (3 papers)
Partner nations: Netherlands United States Sweden

In The Last Decade

Sander Bins

55 papers receiving 1.2k citations

Peers

Countries citing papers authored by Sander Bins

Since Specialization

Citations

This map shows the geographic impact of Sander Bins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sander Bins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sander Bins more than expected).

Fields of papers citing papers by Sander Bins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sander Bins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sander Bins. The network helps show where Sander Bins may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Sander Bins, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Sander Bins Line = papers co-authored together Sander Bins links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	611O Updated results from BNT211-01 (NCT04503278), an ongoing, first-in-human, phase I study evaluating safety and efficacy of CLDN6 CAR T cells and a CLDN6-encoding mRNA vaccine in patients with relapsed/refractory CLDN6+ solid tumors Annals of Oncology ·Sudheer Obbu,Andréas Mackensen,Min Ji Suh,Winfried Alsdorf,Ting-Ying Wu,Daniel Heudobler,ปิยาภรณ์ สุนทองห้าว,Antonia Busse,Stephan Mielke,Sander Bins,Guy Ungerechts,Carsten Bokemeyer,Sebastian Klobuch,Nadine Kutsch,Fabian Müller,Susumu Banno,Zhong Wei,Tatsuhiko Kikugawa,Kong XiangJin,Uğur Şahin	2024	7
2	The effect of administering preprocedural VITamin K on the international normalized ratio in patients anticoagulated with ACEnocoumarol (VITKACE-study): a prospective cohort study Journal of Thrombosis and Haemostasis ·М.В. Королев,崔珣,Jeferson Henrique dos Reis Lopes,Dylan J. Naeger,Maurits J. van der Veen,Henk J Adriaansen,María Ángela Ramírez-Cruz,小関健一,Радюкова,Z. Grudziński,Wagnild Jp,Magdalena Medved,肖宪,Sander Bins,Gerjo A. Velders,Patrick K. Jones	2024	0
3	Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1 Clinical Pharmacokinetics ·Mirjam de With,Leni van Doorn,Ainur I. Mursalimov,Kesakichi Isigaki,Maja Matić,高橋伸典,Esther Oomen‐de Hoop,Esther van Meerten,Ron H. N. van Schaik,Ron H.J. Mathijssen,Sander Bins	2023	7
4	Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD Biomedicine & Pharmacotherapy ·Mirjam de With,Leni van Doorn,Oğuz Yaman,Mengyu Ma,Esther Oomen‐de Hoop,Bianca Mostert,Marjolein Y.V. Homs,Samira El Bouazzaoui,Ron H.J. Mathijssen,Ron H. N. van Schaik,Sander Bins	2023	13
5	Abstract C152: Preclinical and emerging Phase 1 study data indicates that novel deuterated MET kinase inhibitor DO-2 mitigates the side effects seen with current approved MET kinase inhibitors: Preventing deleterious ‘de-hinging’ to improve tolerability Molecular Cancer Therapeutics ·Timothy Perera,Laurence Mévellec,Hans Prenen,H. H. Parsons,Debbie Robbrecht,Sander Bins,Горбатова Ермоня Мишаевна,Peter de Bruijn,Jean‐Pascal Machiels,Rachel Galot,Courtney Scantlin,A.N.H. Weel,Irena Loryan,Yang Hu,Oh C E,Jaap Verweij	2023	1
6	Review – The impact of pharmacogenetics on the outcome of immune checkpoint inhibitors Cancer Treatment Reviews ·Karlijn de Joode,Hossein Farahini,Edwin A. Basak,Sander Bins,Astrid A.M. van der Veldt,Ron H. N. van Schaik,Ron H.J. Mathijssen	2023	2
7	Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study European Journal of Cancer ·Edwin A. Basak,電気学会絶縁材料耐トラッキング性調査専門委員会,Karlijn de Joode,Daan P. Hurkmans,SiYong Cheng,Esther Oomen‐de Hoop,Marco W.J. Schreurs,Sander Bins,Stijn L.W. Koolen,Reno Debets,Astrid A.M. van der Veldt,Joachim G.J.V. Aerts,Arjen Joosse,Ron H.J. Mathijssen	2022	13
8	Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy Cancers ·Mirjam de With,Daan P. Hurkmans,Esther Oomen‐de Hoop,Reza Ghoreshi,Sander Bins,Samira El Bouazzaoui,Mandy van Brakel,Reno Debets,Joachim G.J.V. Aerts,Ron H. N. van Schaik,Ron H.J. Mathijssen,Astrid A.M. van der Veldt	2021	9
9	Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma Pharmaceuticals ·Koen G. A. M. Hussaarts,Leni van Doorn,Sander Bins,Dave Sprengers,Peter de Bruijn,Roelof W. F. van Leeuwen,Stijn L.W. Koolen,Teun van Gelder,Ron H.J. Mathijssen	2021	8
10	The Influence of Body Composition on the Systemic Exposure of Paclitaxel in Esophageal Cancer Patients Pharmaceuticals ·Leni van Doorn,E. Revanth,Hánah N. Rier,Jeroen L.A. van Vugt,Charlotte van Kesteren,Sander Bins,Ron H.J. Mathijssen,Mark‐David Levin,Stijn L.W. Koolen	2021	5
11	Tissue Type Differences in ABCB1 Expression and Paclitaxel Tissue Pharmacokinetics in Patients With Esophageal Cancer Frontiers in Pharmacology ·Ruben A.G. van Eerden,Leni van Doorn,Femke M. de Man,Hossein Farahini,Michail Doukas,Thierry P. P. van den Bosch,Esther Oomen‐de Hoop,Peter de Bruijn,Sander Bins,Sinead T. Salandy,G.H. Liu,Lena E. Friberg,Stijn L.W. Koolen,Manon C.W. Spaander,Ron H.J. Mathijssen	2021	7
12	CYP3A4∗22 Genotyping in Clinical Practice: Ready for Implementation? Frontiers in Genetics ·Mengyu Ma,Ruben A.G. van Eerden,Mirjam de With,Laure Elens,Dennis A. Hesselink,Maja Matić,Sander Bins,Ron H.J. Mathijssen,Ron H. N. van Schaik	2021	45
13	Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib Pharmaceutics ·Koen G. A. M. Hussaarts,Leni van Doorn,Karel Eechoute,Jeffrey Damman,Qiang Fu,J H Guo,Eric D. Eisenmann,Alice A. Gibson,Esther Oomen‐de Hoop,Peter de Bruijn,Sharyn D. Baker,Stijn L.W. Koolen,Teun van Gelder,Roelof W. F. van Leeuwen,Ron H.J. Mathijssen,Alex Sparreboom,Sander Bins	2020	10
14	Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients Thyroid ·Edwin A. Basak,R.H. Dee,Daan P. Hurkmans,Marco W.J. Schreurs,Esther Oomen‐de Hoop,Astrid A.M. van der Veldt,Sander Bins,Arjen Joosse,Stijn L.W. Koolen,Reno Debets,Robin P. Peeters,Joachim G.J.V. Aerts,Ron H.J. Mathijssen,Marco Medici	2020	64
15	The influence of single-nucleotide polymorphisms on overall survival and toxicity in cabazitaxel-treated patients with metastatic castration-resistant prostate cancer Cancer Chemotherapy and Pharmacology ·Albertus Bayu Prakoso,Mirjam de With,Rajbir Singh,Muhammad Ikhsan Zulfatan Runtukahu,Samira El Bouazzaoui,Esther Oomen‐de Hoop,Ronald de Wit,Ron H. N. van Schaik,Ron H.J. Mathijssen,Sander Bins	2020	6
16	Correlation between nivolumab exposure and treatment outcomes in non–small-cell lung cancer European Journal of Cancer ·Edwin A. Basak,Stijn L.W. Koolen,Daan P. Hurkmans,Marco W.J. Schreurs,Sander Bins,Esther Oomen‐de Hoop,Annemarie Wijkhuijs,Suresh Kommu,Stefan Sleijfer,Reno Debets,Astrid A.M. van der Veldt,Joachim G.J.V. Aerts,Ron H.J. Mathijssen	2019	54
17	A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients Journal for ImmunoTherapy of Cancer ·Daan P. Hurkmans,Edwin A. Basak,N. Ba-Diop,João Eudes Bezerra Filho,Marco W.J. Schreurs,Annemarie Wijkhuijs,Sander Bins,Esther Oomen‐de Hoop,Reno Debets,Markus Joerger,Arlette E. Odink,Astrid A.M. van der Veldt,Cor H. van der Leest,Joachim G.J.V. Aerts,Ron H.J. Mathijssen,Stijn L.W. Koolen	2019	66
18	Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II Study Clinical Cancer Research ·Annemieke J.M. Nieuweboer,Anne‐Joy M. de Graan,Paul Hamberg,Sander Bins,Robert J. van Soest,Robbert J. van Alphen,Andries M. Bergman,Aart Beeker,Henk van Halteren,Albert J. ten Tije,Michelle Udayamurthy,Erik K. Fromme,Dana Chiţu,Ronald de Wit,Ron H.J. Mathijssen	2016	12
19	The time to progression ratio: a new individualized volumetric parameter for the early detection of clinical benefit of targeted therapies Annals of Oncology ·Marisela Árraga de Montiel,Fleur Weeber,Sander Bins,Christa G.M. Gadellaa-van Hooijdonk,Erik van Werkhoven,Stefan M. Willems,Marijn van Stralen,Wouter B. Veldhuis,Inge Ubink,Neeltje Steeghs,Maja J. De Jonge,Marlies H.G. Langenberg,Jan H.M. Schellens,Stefan Sleijfer,Martijn P. Lolkema,Emile E. Voest	2016	14
20	Comparative efficacy of zafirlukast and low dose steroids in asthmatics on prn beta2-agonists L. A. Laitinen,Ian Naya,Sander Bins,J.R. Reddington	1997	27

About Sander Bins

Sander Bins is a scholar working on Oncology, Internal Medicine, Pulmonary and Respiratory Medicine, Hematology and Cancer Research, having authored 59 papers that have together received 1.2k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (20 papers), Pancreatic and Hepatic Oncology Research (12 papers), Colorectal Cancer Treatments and Studies (10 papers), Lung Cancer Treatments and Mutations (9 papers), Drug Transport and Resistance Mechanisms (8 papers), CAR-T cell therapy research (5 papers), Prostate Cancer Treatment and Research (5 papers) and Cancer therapeutics and mechanisms (4 papers). The work is most often cited by research in Oncology (688 citations), Pharmacology (97 citations), Pulmonary and Respiratory Medicine (324 citations), Cancer Research (117 citations) and Hematology (86 citations). Sander Bins has collaborated with scholars based in Netherlands, United States and Sweden. Frequent co-authors include Ron H.J. Mathijssen, Ron H. N. van Schaik, Femke M. de Man, Andrew K.L. Goey, Esther Oomen‐de Hoop, Stijn L.W. Koolen, Joachim G.J.V. Aerts, Reno Debets, Astrid A.M. van der Veldt and Edwin A. Basak. Their work appears in journals such as Annals of Oncology, Clinical Pharmacokinetics, Clinical Cancer Research, European Journal of Cancer and Biomedicine & Pharmacotherapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact